The therapeutic treatment of osteosarcoma (OS), a rare malignant teenage cancer of the skeletal system, still represents a great challenge as patient survival after conventional protocol chemotherapy treatment has not improved in the last four decades leaving poor patient prognoses. Therefore, many efforts have been done to find increasingly reliable OS cell models and to identify "druggable" targets in OS, in order to identify novel effective therapeutic approaches and treatment strategies. In this contest, the more successful use of patientderived cell cultures in respect to human commercial lines and findings of Src kinase deregulation in cancer, prompted us to study for the first time the activation state of Src and the potential activity of our Src inhibitor SI-83 in a number of chemo-na€ ıve patient-derived primary OS cells. We here demonstrate that Src is hyperactivated in OS cells in respect to the nonmalignant counterpart and that SI-83 is able to strongly decrease cell viability, proliferation, Src 416 phosphorylation, and cell migration.
Introduction
Osteosarcoma (OS) is one of the most common malignant rare tumors of the skeletal system and mainly occurs in young people aged 15-19 years. It originates from mesenchymal cells and is characterized by fusiform stromal cells producing immature bone or osteoid tissue. Due to its rapid progression and poor prognosis, combined with 85% of metastasis rate to the lung, OS is a major death-causing disease in adolescence [1] . Although 60-70% of OS patients achieve 5-year diseasefree survival due to the current treatments, including surgery, polychemotherapy, and radiation therapy, 20-25% of patients have lung metastases when diagnosed and there are still Abbreviations: OS, Osteosarcoma; pSrc 416 , Src phosphorylation on tyrosine 416; HOb, Human primary osteoblasts; Src-tot, Src total; DMEM, Dulbecco's modified eagle's medium; FCS, Fetal calf serum; DMSO, Dimethyl sulfoxide; MTT, Thiazolyl blue tetrazolium bromide; LD 50 , Half-maximal lethal dose; RIPA, Radio-immunoprecipitation assay; BCA, Bicinchoninic acid; SDS-PAGE, Sodium dodecyl sulfate polyacrylamide gel electrophoresis; ECL, Enhanced chemiluminescence; IC 50 , Half-maximal inhibition concentration; DT, Doubling time; ANOVA, Analysis of variance Additional Supporting Information may be found in the online version of this article.
further patients who develop lung metastasis during treatment [2] . Moreover, the conventional protocol chemotherapy treatment, established in the 1970s, which includes cisplatin, doxorubicin, ifosfamide, and high dose methotrexate [3] , has reached a plateau of efficacy and the patient survival rate has not improved in the last four decades with poor patient prognoses even after receiving systemic treatment [4] . The use of novel effective therapeutic approaches and treatment strategies are thus required to improve the prognosis for OS patients, especially for those who are resistant to current therapy. In the last years, attempts to identify "druggable" targets in OS have shown a complex karyotype and principally multiple interacting and deregulating protein pathways implicated in the development of OS, among which tyrosine kinases, and in particular Src, are the central hub [3] . Src is a nonreceptor tyrosine kinase which is involved in intracellular signal transduction processes, and its activation in cancer influences cellular proliferation, invasiveness, and metastasis [5] . Src deregulation in cancer primarily involves protein overexpression and abnormalities in Src kinase activity, mostly due to autophosphorylation of tyrosine 416 (pSrc 416 ), which can in turn activate specific signaling pathways by phosphorylating the target proteins, thus constituting an amplification cascade of a network regulation system [6] . Although different sarcoma cells and tissue specimens showed to possess hyperphosphorylated Src 416 [6, 7] , to date Src activation levels (both Src 416 hyper-phosphorylation and total Src amount) remained still fully unexplored in human primary OS chemo-na€ ıve cells which are known to be invaluable biological systems for the study of the molecular basis of the disease and the development of novel targeted therapeutic approaches [8, 9] [10, 11] . To our knowledge, this is the first study on the basal activation state of Src kinase in patient derived chemo-na€ ıve cells (compared to human primary osteoblasts, HOb) and the possible correlation between levels of pSrc 416 and Src-tot and OS subtype.
Recently, as Src became an active target for cancer drug development, a number of Src inhibitors, including Dasatinib, have been preclinically and clinically evaluated for solid tumor treatment, including OS. However, there are OS cells, such as MG63, which do not respond to Src inhibitors [7, 12] , leaving Src targeting still a great challenging.
In the last years, we selected a pyrazolo [3,4-d] pyrimidine derivative, namely SI-83, for its high antiproliferative and proapoptotic activity toward a subset of commercial human OS cells, as well as for its ability to inhibiting Src 416 phosphorylation in SaOS2 cells [13] [14] [15] [16] [17] . SI-83 marginally affected proliferation and apoptosis in HOb and did not impair osteoblastic differentiation and functionality [13, 14, 18] . Moreover, SI-83 significantly reduced tumor mass in a xenograft SaOS2 murine model without apparent toxicity for animals [13, 14] . By means of a combined proteomic and phosphoproteomic approach, we were also able to get insight into the molecular targets of SI-83 [17] and thus to define the mechanism of SI-83-induced apoptosis (endoplasmic reticulum stress), inhibition of proliferation (through inhibition of both de novo and salvage nucleotide pathways), and inhibition of migration and adhesion (alteration of cytoskeleton organization and of actin polymerization).
Here, we report, for the first time, evaluation of Src activation in respect to the nonmalignant counterpart (HOb) and biological evaluation of SI-83 on chemo-na€ ıve patient-derived OS primary cells. These unique and successfully OS models [8] are crucial for the development of new molecules for the treatment of this cancer, as the rarity of the disease, the difficulties in obtaining sufficient amounts of chemo-na€ ıve tumor tissue and the hardness to obtain relatives cell cultures, severely limit OS investigational in vitro and in vivo studies [9] [10] [11] .
In this work, we demonstrated the prominence of Src activation in a subset of OS cells in respect to HOb and proved the efficacy of SI-83 to significantly inhibit cell viability, Src 416 phosphorylation, and cell migration in human OS chemo-na€ ıve primary cells and commercial cell lines.
Experimental procedures
The whole study was conducted following the approval of Florence University Hospital Ethics Committee, namely ''Comitato Etico Locale dell'Azienda Ospedaliera-Universitaria Careggi''. The investigation conformed to the principles outlined in the 1975 Declaration of Helsinki and its later amendments. The patients gave a written informed consent prior to inclusion in the study.
All reagents were from Sigma-Aldrich (St. Louis, MO), if not differently specified. Ultrapure water was prepared from a Milli-Q system (Millipore, Bedford, MA).
Cell source and culture
Human primary chemo-na€ ıve OS cell cultures (OS1, OS2, OS3, and OS5) were obtained in our laboratory and characterized as reported [8] , while the human OS commercial cell lines MG63 (ATCC-CRL-1427), TE85 (ATCC-CRL-1543) and U2OS (ATCC-HTB-96), were obtained from American Type Culture Collection (ATCC, Manassas, VA). Human primary osteoblasts (HOb) were isolated and cultured as described [18] . Each cell culture was maintained in DMEM supplemented with 10% FCS, 2 mM L-glutamine, 100 U/mL penicillin and 100 lg/mL streptomycin (henceforth referred to as complete DMEM) at 378C in a humidified atmosphere of 5% CO 2 -95% air. Comparative analysis was performed with cell populations at the same generation, if not differently specified.
Cell treatments
Pyrazolo [3,4- fitting. Data were reported as the inhibitory concentration required to achieve 50% inhibition relative to control reaction (IC 50 ).
Migration assays
Migration was evaluated by wound-healing assay using Ibidi Culture-Insert (Ibidi) [8] . SI-83 concentrations were chosen accordingly to LD 50 values and DMSO was used as control. SI-83 incubation time was chosen according to the doubling time (DT) of each OS cell populations [8, 9] , as cell duplication and spreading surely influence cell migration. The gap widths (lm) were measured, at DT/4, DT/2, and DT time points, both in SI-83-treated and in DMSO-treated cells on the digitalized images using AxioVision rel. 4.8 software, and migration rate (slope) was calculated by regression analysis with OriginV R -Data Analysis and Graphing Software using linear curve fitting. Each experiment was performed in triplicate.
Statistical analysis
All experiments were carried out in triplicate; data are presented as average values with standard error. Unpaired Student's t test and multiple measures ANOVA analysis followed by the Bonferroni-type multiple comparison were used when necessary. Differences with at least a P value 0.05 were considered significant. Correlation coefficient (r) was calculated by the Pearson product-moment correlation coefficient, and statistical significance (P value) was analyzed using t approximation.
Results

Src kinase was hyperactivated in human OS cells in respect to HOb
All OS commercial cell lines (TE85, U2OS, and MG63) and OS chemo-na€ ıve primary cells (OS1, OS2, OS3, and OS5) showed an increase of both Src-tot and pSrc 416 levels in comparison to HOb (Figs. 1A and 1B) . In particular, the increase of tot-Src levels were maintained around 2-fold change value, while pSrc 416 levels reached different and higher levels: MG63 cells showed the most notably increase of pSrc 416 level, which was 7.28-fold higher than the HOb level, followed by U2OS (7.25-fold), TE85 (5.8-fold), OS2, OS3, and OS5 (around 3-fold) and OS1 (2.43-fold). Levels of Src-tot and pSrc 416 (Table 1) showed a significant correlation only in MG63, TE85, U2OS, and OS1 cell types (P < 0.05, Fig. 1C ).
SI-83 inhibits cell viability in four human OS primary cells
SI-83 showed a dose-dependent inhibition of cell viability in all four human OS primary cells tested ( Fig. 2A; Table 1 ). In particular, OS3 and OS1 were more responsive to the activity of Data were reported as mean 6 SD of three independent experiments; data were statistically significant if not differently indicated (P > 0.05); sign 1 indicates increase in fold change in respect to HOb. 416 and Src-tot. Experiments were performed in triplicate. Bars represent mean 6 SD. *P < 0.05 and **P < 0.01 compared with the value in the DMSO-treated cells; #P < 0.05 and ## P < 0.01 compared with treated cells (50 lM SI-83).
FIG 3
Src 416 phosphorylation is decreased after SI-83 treatment in human OS commercial cell lines. Cells were treated with escalating doses of SI-83 for 6 h before their lysis. A: Western blotting images representing Src 416 phosphorylation status (first lane), endogenous levels of Src-tot protein (second lane) and GAPDH content (third lane). B: Graphs reports the optical density values relative to immunoreactive bands of pSrc 416 and Src-tot. Experiments were performed in triplicate. Bars represent mean 6 SD. *P < 0.05 and **P < 0.01 compared with the value in the DMSO-treated cells.
FIG 4
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75 lM SI-83 (Fig. 3A) . However, only the upper bands were considered during the optical density analysis, since the remaining bands had a lower molecular weight in respect to Src and they could represent cross-reacting SFK proteins (as reported also in anti-pSrc 416 antibody data sheet).
After SI-83 treatment, Src-tot level was increased significantly in a dose-dependent manner in OS1, OS3, and TE85 cells while it was decreased in the other cell types (Figs. 3 and  4) . In OS5, significant decrease of Src-tot level was observed only at 75 lM (0.54-fold change vs. DMSO) (Figs. 3 and 4) . In OS2 cells, as observed for Src 416 phosphorylation, the lowest SI-83 doses led to a significantly decrease of Src-tot level in respect to DMSO, although a significant increase was observed at the highest SI-83 dose. However, such an increase did not overcome baseline Src-tot levels (Fig. 3B) .
All the cells types (apart OS2) showed a significant correlation between pSrc 416 IC 50 and Src hyperactivation (pSrc 416 / Src-tot) (P < 0.05, Supporting Information Fig. 1A ): the higher Src hyperactivation, the more sensitive the OS cell lines were to SI-83 capability to decrease pSrc 416 .
A significant correlation (P < 0.05, Supporting Information Fig. 1B) 
SI-83 inhibits migration in human OS primary cells and human OS commercial cell lines
Evident from Fig. 5 , SI-83 was able to inhibit cellular migration in all the cell types, except OS3 (P > 0.05), with very different migration rate inhibition capability which ranges from 20.79% (OS2) to 50.45% (OS1) in respect to DMSO (Table 1) .
No significant correlation could be done between Src hyperactivation (pSrc 416 /Src-tot) or SI-83 pSrc 416 IC 50 and SI-83 inhibition of migration rate.
Discussion
During the past decade, Src has interested researchers as a therapeutic target [5] since it orchestrates numberless fundamental cellular processes, such as cell proliferation, migration, invasion and survival [13, 14, 17, 19, 20] . Although activating Src mutations are rarely associate with human cancer, both overexpression and over-activation of Src, mainly due to Src 416 auto-phosphorylation, have been shown to contribute to transformation and malignant cancer progression [19] .
In the present study, we have demonstrated that human chemo-na€ ıve OS primary cells OS1, OS2, OS3, and OS5 showed both Src 416 hyper-phosphorylation and increased levels of Srctot in respect to HOb, providing the first experimental models of Src hyper-activation in patient-derived OS cells and SI-83 inhibits migration rate in human OS primary cells and commercial cell lines. Cells were treated with SI-83 at their corresponding LD 50 for a time equivalent to their DT. A: Cell migration was visualized at 310 magnification by light microscopy and photographed with a digital camera. For OS1, OS5, TE85, U2OS, and MG63 at the end of treatment (DT) the front of migration was entirely closed (data not shown) and representative images correspondent to DT/2 were therefore chosen. B: Graphs reports the percentage of migration rate in cells treated with SI-83 in respect to their respective DMSO treated cells. Experiments were performed in triplicate. Bars represent mean 6 SD. *P < 0.05 and **P < 0.01 compared with the value in the DMSO treated cells. Two column fitting image.
FIG 5
suggesting that both pSrc 416 and Src-tot levels contribute to Src kinase activity in cancer cells in respect to the nonmalignant counterpart. We have validated these results also in TE85, U2OS and MG63 human OS commercial lines. Although in a subset of cells examined (OS2, OS3, and OS5) Src-tot levels did not correlate with levels of pSrc 416 , indicating different levels of Src kinase activation, these data highlighted and confirmed the pivotal role of Src kinase activation in OS pathogenesis [8, 14] . As a consequence, our results suggested the use of baseline Src-tot and pSrc 416 levels as useful predictive biomarker to determine OS malignant phenotype and to indicate specifically the prognosis of OS. Indeed, OS1 cells, isolated by us [8] from a chondroblastic OS, which was associated to a better prognosis [21] , possessed lower levels of both Src-tot and Src 416 phosphorylation in respect to OS2 and OS5 which became from worse outcome osteoblastic OS [21] . Although our results became from a small subset of OS cells and require future validation in a greater number of human primary chemo-na€ ıve cells, they should be anyway considered reliable bearing in mind the rarity of the disease and especially the hardness to obtain and therefore the scarcity of human primary OS chemo-na€ ıve cells.
Moreover, results obtained reinforced the rationale for the development of Src inhibitors for OS treatment [22] and strongly encouraged the use of our chemo-na€ ıve cell models, which possessed pSrc 416 and Src-tot high baseline levels, for the selection and the study of new Src inhibitors [8, 14, 17] .
In such a context our pyrazolo [3,4-d] pyrimidine derivative SI-83 pSrc 416 inhibitor fully fitted as a chemical scaffold with proved activity towards SaOS-2 cells and very low toxicity for non-neoplastic cells (HOb) [14, 17] .
In this work, for the first time, SI-83 has been challenged on human OS chemo-na€ ıve primary cells and its capability to inhibit Src activation and cell migration has been also confirmed in three additional human OS commercial cell lines (U2OS, TE85, and MG63). For U2OS, TE85, and MG63 SI-83 LD 50 was already been calculated by us previously [14] (Table 1) .
In particular, SI-83 led to a considerable reduction of cell viability in all the four human primary OS cells, being OS1, OS3, and OS5 LD 50 lower, or similar in case of OS2, to that determined by us [14] on MG63 cell line (LD 50 50 mM) (Table  1) . Importantly, SI-83 marginally affected HOb viability when used at the LD 50 of OS cells and also at higher concentrations. On the other hand, Dasatinib (actually the reference compound for Src inhibitors) showed toxicity toward different osteblastic cells also at concentrations lower than 100 lM [23] [24] [25] .
Thus, although LD 50 values towards chemo-na€ ıve cells could be considered quite high (also depending by the aggressive subtype of these OS primary cells, as will be discussed shortly) it could be concluded that SI-83 was able to inhibit OS cells viability without affect normal cells (Fig. 2C) , which obviously represents a crucial feature.
The different response of the chemo-na€ ıve primary cells toward SI-83 may be in agreement with their OS subtype, as in the three major previous studies regarding the relationship between OS subtype and survival, the chondroblastic subtype showed better survival and better response to preoperative chemotherapy than the osteoblastic subtype did [26] . Indeed, in the present work we had found that OS2 and OS5, which are osteoblastic OS cell cultures [8] , were less sensitive to SI-83 in respect to the chondroblastic OS1 cells. For SI-83, a proved relationship between the compound capability to reduce cell viability and OS subtype has been found for OS commercial cell lines in our previous work [14] where MG63 cells (fibroblastic derivation) showed the highest LD 50 in respect to the other cells tested (epithelial-fibroblastic derivation). In the same way, the higher LD 50 values of SI-83 towards human OS primary cells in respect to that reported by us for OS commercial cell lines [14] in the same experimental condition (i.e., without serum starvation) could be attributed to the lower chemotherapy sensitivity of the osteoblastic and chondroblastic OS subtype (OS2 and OS5, OS1) in respect to the epithelial or mixed epithelial-fibroblastic ones (SaOS-2 and U2OS, MNNG and TE85) ( Table 1 ) [27] .
Notably, high Src activation (both increased Src-tot and Src 416 phosphorylation levels) correlated with low LD 50 values in 5/7 cell types (OS1, OS3, OS5, TE85, U2OS), thus indicating a compound responsiveness in cells with much more upregulated Src pathway.
SI-83 has previously been shown to directly inhibit Src activity (i.e., Src 416 phosphorylation) in SaOS-2 cells [14, 17] . Now, we demonstrated the heterogeneous ability of SI-83 to strongly decrease Src 416 phosphorylation in all the cell types tested. The inverse correlation found between IC 50 and basal pSrc 416 activation once again pointed out the higher susceptibility to SI-83 activity by those OS cells which possessed higher pSrc 416 phosphorylation levels. Consequently, since SI-83 influences only moderately HOb growth (Fig. 2C) [13, 14] , it can be assumed that SI-83 activity towards abnormal tumor cells was linked to Src hyper-phosphorylation.
Interestingly, also Src-tot amount was negatively affected by SI-83 treatment. Although this phenomenon occurred only in MG63, U2OS, and OS5 at the highest concentration, these data pointed out the great efficacy of SI-83 in counteracting OS Src-deregulated pathway, acting both on Src 416 phosphorylation and Src-tot levels.
On the other hand, dose-dependent increase of Src-tot protein levels in a subset of cells treated with SI-83 (TE85, OS1, and OS3) suggested a positive feedback mechanism for compensation of Src kinase inhibition with increased levels of protein.
In OS2 cells, Src 416 phosphorylation and Src-tot levels after SI-83 treatment had a peculiar trend: after their initial dosedependent decrease, a significant increase at the highest SI-83 concentration (anyway lower than DMSO level) was observable. While for Src-tot the increase could be explained by the same positive feedback mechanism described above, the significance of Src 416 phosphorylation increase still remained not completely understood.
Our data showed that LD 50 and IC 50 values had a significant positive correlation in all the cell types (except MG63).
Moreover, for OS1, MG63, TE85, and U2OS, IC 50 values lower than LD 50 ones suggested that in these cells viability was modulated mostly by Scr activity. On the contrary, IC 50 values higher than the LD 50 ones, as observed for OS3 and OS5, indicated that Src might not be the sole or the major target of SI-83 and that cell viability might be regulated through a Srcindependent pathway. Indeed, it has been previously demonstrated by us that SI-83 was able to moderately inhibit, in vitro, other tyrosine kinases [13, 15] and that the inhibition of SaOS-2 cell growth upon treatment with SI-83 resulted from a combination of targeting either Src or Abl [13, 14, 17] . Moreover, a comparative proteomic and phosphoproteomics approach on SaOS-2 cells also evidenced that the antiproliferative activity of SI-83 may be exerted by proteins involved in both de novo and salvage nucleotide synthesis, such as NDPKA, APRT, and ATIC, which were respectively downregulated or dephosphorylated, without the involvement of Src downstream effector Akt [17] . Another explanation could be that Src is not required for survival or that low levels of Src kinase activation are sufficient to induce the biological properties.
As one of the major problem in OS survival is represented by the easily metastasis overcoming, we investigated the functional effect of SI-83 on cell migration. Time-course experiments revealed that SI-83 was able to inhibit cellular migration in all the cell types. Unfortunately, it was not possible to correlate SI-83 migration inhibition neither with cellular metastatic phenotype, based on different ezrin expression [8] nor with Src activation or Src SI-83 IC 50 values. This implied that, within the group of cells analyzed, different Src activation levels and different SI-83 pSrc 416 inhibition levels were not predictive of the amount of SI-83 migration rate inhibition. However, the great capability of SI-83 to modulate cell migration, possibly through inhibition of pSrc 416 phosphorylation, was here showed.
Conclusions
In this work, we demonstrated that Src activation represents a key molecular signature for OS malignant phenotype and that pyrazolo [3,4-d] pyrimidine Src-inhibitor SI-83 is able to inhibit fundamental Src-mediated cellular processes, such as proliferation and migration, that are two out of the six so-called "hallmarks of cancer" [28] . SI-83 resulted active in a wide panel of OS cells, included a set of human OS chemo-na€ ıve primary cells. The use of reliable OS cell models that reflect the heterogeneity of human OS population, strongly support the use of SI-83 as a scaffold for the development of novel therapeutic strategies for OS.
